Akimitsu Miyake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akimitsu Miyake has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Hagihara
Research Institute for Microbial Diseases (RIMD), Osaka University , Suita
2 shared publications - Michiko Matsunaga
Graduate School of Education, Kyoto University , Kyoto
2 shared publications - Sayaka Hotta
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita 565-0871, Osaka, Japan
2 shared publications - Aya K. Takeda
Cykinso, Inc., 1-36-1 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan
1 shared publication - Chise Yamaguchi
Division of Nutritional Management, Osaka University Hospital, Osaka 565-0871, Japan
1 shared publication - Hitomi Saito
Department of Advanced Hybrid Medicine, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
1 shared publication
Latest Publications
- Open Access
Gut Microbiota Enterotype as a Predictor of Sarcopenia in the Japanese Elderly Population
Background/Objectives: Frailty and sarcopenia are age-related conditions that impair quality of life in older adults. Although the gut microbiota affects muscle health, its role in sarcopenia remains unclear. This study investigated the association between gut microbiota enterotypes and sarcopenia in community-dwelling older Japanese adults. Methods: In this cross-sectional study, 322 community-dwelling adults from the Japanese Frailty Scale cohort aged ≥65 years were assessed for sarcopenia using standardized criteria. Physical measures included grip strength, gait speed, and skeletal muscle mass index (SMI). Gut microbiota profiles were analyzed using 16S rRNA sequencing and classified into four enterotypes (ET-B1, ET-B2, ET-R, ET-P). Associations with sarcopenia were evaluated using multivariable logistic regression. Results: Participants with enterotype ET-B2 had significantly lower microbial diversity (p < 0.01) and reduced grip strength (p < 0.05), whereas the difference in SMI compared with ET-P individuals did not reach statistical significance (p = 0.0625). Sarcopenia prevalence differed significantly between enterotypes (p < 0.01). A predictive model incorporating age and ET-B2 exhibited an area under the receiver operating characteristic curve (AUC) of 0.795, significantly higher than the age-only model (AUC = 0.686, DeLong’s test, p < 0.05). Conclusions: Gut microbiota composition, especially enterotype ET-B2, is significantly associated with sarcopenia in older Japanese adults. These findings indicate the potential for using the gut microbiota as a biomarker and therapeutic target in treating age-related muscle decline.
Open AccessGut Microbiota Enterotype as a Predictor of Sarcopenia in the Japanese Elderly Population
Background/Objectives: Frailty and sarcopenia are age-related conditions that impair quality of life in older adults. Although the gut microbiota affects muscle health, its role in sarcopenia remains unclear. This study investigated the association between gut microbiota enterotypes and sarcopenia in community-dwelling older Japanese adults. Methods: In this cross-sectional study, 322 community-dwelling adults from the Japanese Frailty Scale cohort aged ≥65 years were assessed for sarcopenia using standardized criteria. Physical measures included grip strength, gait speed, and skeletal muscle mass index (SMI). Gut microbiota profiles were analyzed using 16S rRNA sequencing and classified into four enterotypes (ET-B1, ET-B2, ET-R, ET-P). Associations with sarcopenia were evaluated using multivariable logistic regression. Results: Participants with enterotype ET-B2 had significantly lower microbial diversity (p < 0.01) and reduced grip strength (p < 0.05), whereas the difference in SMI compared with ET-P individuals did not reach statistical significance (p = 0.0625). Sarcopenia prevalence differed significantly between enterotypes (p < 0.01). A predictive model incorporating age and ET-B2 exhibited an area under the receiver operating characteristic curve (AUC) of 0.795, significantly higher than the age-only model (AUC = 0.686, DeLong’s test, p < 0.05). Conclusions: Gut microbiota composition, especially enterotype ET-B2, is significantly associated with sarcopenia in older Japanese adults. These findings indicate the potential for using the gut microbiota as a biomarker and therapeutic target in treating age-related muscle decline.
- Open Access
Long-Term Effects of a Ketogenic Diet for Cancer
A ketogenic diet has been proposed as a potential supportive therapy for cancer patients, although its long-term influence on survival rates remain controversial. In our previous report, we presented promising results for 37 of 55 patients with advanced cancer enrolled between 2013 and 2018 who remained on a ketogenic diet for at least 3 months. We followed all 55 patients until March 2023 and analyzed the data up to March 2022. For the 37 patients with previously reported promising results, the median follow-up period was 25 (range of 3–104) months and 28 patients died. The median overall survival (OS) in this subset of 37 patients was 25.1 months and the 5-year survival rate was 23.9%. We also evaluated the association between the duration of the ketogenic diet and outcome in all 55 patients, except for 2 patients with insufficient data. The patients were divided into two groups: those who followed the diet for ≥12 months (n = 21) and those who followed it for n = 32). The median duration of the ketogenic diet was 37 (range of 12–99) months for the ≥12 months group and 3 (range of 0–11) months for the p < 0.001, adjusted log-rank test). These results indicate that a longer continuation of the ketogenic diet improved the prognosis of advanced cancer patients.
Open AccessLong-Term Effects of a Ketogenic Diet for Cancer
A ketogenic diet has been proposed as a potential supportive therapy for cancer patients, although its long-term influence on survival rates remain controversial. In our previous report, we presented promising results for 37 of 55 patients with advanced cancer enrolled between 2013 and 2018 who remained on a ketogenic diet for at least 3 months. We followed all 55 patients until March 2023 and analyzed the data up to March 2022. For the 37 patients with previously reported promising results, the median follow-up period was 25 (range of 3–104) months and 28 patients died. The median overall survival (OS) in this subset of 37 patients was 25.1 months and the 5-year survival rate was 23.9%. We also evaluated the association between the duration of the ketogenic diet and outcome in all 55 patients, except for 2 patients with insufficient data. The patients were divided into two groups: those who followed the diet for ≥12 months (n = 21) and those who followed it for n = 32). The median duration of the ketogenic diet was 37 (range of 12–99) months for the ≥12 months group and 3 (range of 0–11) months for the p < 0.001, adjusted log-rank test). These results indicate that a longer continuation of the ketogenic diet improved the prognosis of advanced cancer patients.